ACCC is offering two new virtual CE initiatives that leverage small-group learning among clinicians who treat patients with early-stage NSCLC and patients with advanced HER2+ breast cancer.
Optimally treating patients with early-stage NSCLC and patients with advanced HER2+ breast cancer requires navigating an ever-changing landscape of diagnostics and treatment options. Staying knowledgeable of the latest science in the treatment of these complex diseases can be challenging for busy professionals, to say the least.
ACCC is offering two new online continuing education (CE) initiatives that leverage small-group learning among clinicians and their peers who have roles in the care and treatment of patients with early-stage NSCLC and patients with advanced HER2+ breast cancer. The small-group courses—limited to 6-15 people—engage learners in both self-paced self-study and collaborative online group tasks aimed at helping participants learn how to optimally manage their patients.
How It Works
Leading this educational initiative are group leaders who are physicians, advanced practice providers (NPs/PAs), and oncology pharmacists with expertise in NSCLC and HER2+ breast cancer. Participants complete a multi-component curriculum that includes self-study materials, live group discussions, and group challenges. Group leaders focus on mentoring and promoting peer-to-peer learning to establish meaningful, small-group interactions that bring context to the material in the self-study units.
Best Practices in Early-Stage NSCLC
In this course, participants who have roles in the care and treatment of patients with early-stage NSCLC will:
Making Sense of the Evolving Standards of Care for Advanced HER2+ Breast Cancer
In this course, participants who have roles in the care and treatment of patients with advanced HER2+ breast cancer will:
Both courses require a time commitment of 2.5 hours and offer CE credit upon completion. Enroll in Best Practices in Early-Stage NSCLC and Making Sense of the Evolving Standards of Care for Advanced HER2+ Breast Cancer by Nov. 8, 2021, to participate. If you would like to learn more about participating or serving as a group leader, please contact Rukiya Wongus, ACCC Program Manager.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
